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Lipid rafts are membrane domains, more ordered than the bulk membrane and enriched
in cholesterol and sphingolipids. They represent a platform for protein-lipid and protein–
protein interactions and for cellular signaling events. In addition to their normal functions,
including membrane trafﬁcking, ligand binding (including viruses), axonal development and
maintenance of synaptic integrity, rafts have also been implicated in the pathogenesis of
several neurodegenerative diseases includingAlzheimer’s disease (AD). Lipid rafts promote
interaction of the amyloid precursor protein (APP) with the secretase (BACE-1) responsible
for generation of the amyloid β peptide, Aβ. Rafts also regulate cholinergic signaling as well
as acetylcholinesterase and Aβ interaction. In addition, such major lipid raft components
as cholesterol and GM1 ganglioside have been directly implicated in pathogenesis of the
disease. Perturbation of lipid raft integrity can also affect various signaling pathways leading
to cellular death and AD. In this review, we discuss modulation of APP cleavage by lipid
rafts and their components, while also looking at more recent ﬁndings on the role of lipid
rafts in signaling events.
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INTRODUCTION
It has traditionally been difﬁcult to reach any kind of consensus
concerning the deﬁnition of lipid rafts. However, in 2006 at the
Keystone Symposium on Lipid Rafts and Cell Function in Col-
orado it was agreed that “membrane rafts are small (10–200 nm),
heterogeneous, highly dynamic, sterol, and sphingolipid-enriched
domains that compartmentalize cellular processes. Small rafts can
sometimes be stabilized to form larger platforms through protein–
protein and protein-lipid interactions” (Pike, 2006). The long,
saturated acyl chains of sphingolipids allow tight packing hence
their juxtaposition with the kinked, unsaturated acyl chains of
bulk membrane phospholipids leads to phase separation (Brown
and London, 2000). The cholesterol molecules can act as “spac-
ers,” ﬁlling any gaps in sphingolipid packing (Simons and Ikonen,
1997).
The notion of lipid rafts, while not new, has never been far
from controversy (Pike, 2009), their existence frequently ques-
tioned (Munro, 2003). It is almost 30 years since Karnovsky et al.
(1982) suggested that protein diffusion in membranes is not free,
but somehow constrained. They went on to detail the now famil-
iar concept of the organization of lipids in domains, which may
have functional signiﬁcance. The differential detergent (Triton
X-100) solubility of glycosylphosphatidylinositol (GPI)-anchored
proteins and transmembrane proteins was ﬁrst shown by Hooper
and Turner (1988). Later work showed the importance of lipid
rafts in protein sorting and segregation, with GPI anchored pro-
teins being preferentially localized in lipid rafts (Brown and Rose,
1992; Brown and London, 2000; Pike, 2009). Other lipid modiﬁca-
tions of proteins have also been described, such as palmitoylation
and myristoylation which may inﬂuence raft localization (Brown
and London, 2000; Smotrys and Linder, 2004; Pike, 2009). In
describing membrane lipid clusters as moving platforms, or rafts,
which are enriched in both sphingolipids and cholesterol, perhaps
the most important ﬁnding was that proteins could be segregated
being selectively included or excluded from the rafts (Simons and
Ikonen, 1997). In this way, raft localization can serve to facilitate
or obstruct protein interactions (Brown and London, 2000; Ling-
wood and Simons, 2009) or act as a protein scaffold while allowing
diffusion (Maxﬁeld and Tabas, 2005).
Despite signiﬁcant efforts in developingmethodology and tech-
niques for lipid raft research, there are still some shortcomings in
precise determination of their size, structure, and composition
which were recently critically discussed by Simons et al. (2010).
The most important issue which still induces debate is related to
application of detergents for isolation of lipid rafts and methyl-
β-cyclodextrin for extraction of cholesterol from cell membranes
which could lead to formation of artiﬁcial complexes not exist-
ing in the natural environment. It has now been established that
detergent-resistant membranes (DRMs) are not identical to lipid
rafts and the data on proteins detected within DRMs from various
types of cells should be treated with caution and not always con-
sidered to be functionally raft localized (Lichtenberg et al., 2005;
Chen et al., 2009a). Development of a new technique that puriﬁes
nano-meso scale DRMs at 37˚C in an ionic buffer that preserves
the lamellar phase of the metastable inner leaﬂet lipids could be
a signiﬁcant step toward purifying individual physiologically rel-
evant rafts (Morris et al., 2011). Although Triton X-100 is still the
standard detergent in preparation of lipid rafts some groups claim
that use of Brij 96 producesmore reliable results although compar-
ing properties of both detergents in the same set of experiments
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have not produced signiﬁcantly different results. Moreover it has
been suggested that preparation of the rafts in a buffer mimic-
king the cytoplasmic environment will preserve the structure of
the rafts under physiological conditions by retaining the proteins
associatedwith the intracellular part of themembrane (Chen et al.,
2009b).
Another source of controversy in lipid raft research which still
has to be resolved is determined by the lack of suitable detec-
tion techniques in living cells. This resulted in estimation of the
putative size of lipid rafts in the range of 5–700 nm. In the last
decade a number of new techniques assisting in estimation of raft
size and helping in their visualization has been developed and
applied (for review see Simons et al., 2010). They include sin-
gle molecule spectroscopy and super-resolution microscopy such
as ﬂuorescence recovery after photobleaching (FRAP), stimulated
emission depletion (STED), Förster resonance energy transfer
(FRET), total internal reﬂection ﬂuorescence (TIRF), and ﬂu-
orescence correlation spectroscopy (FCS) techniques. However,
even using these techniques the subwavelength lipid domains have
never been directly visualized but their size was predicted to be
<20 nm (Eggeling et al., 2009). Despite the limitations these new
techniques conﬁrmed the existence of nanoscale cholesterol-based
assemblies of lipids and proteins in the membranes of living cells
and allowed to characterize further their dynamics and properties.
When comparing the data on the size and precise protein and
lipid composition of lipid rafts it is important to bear in mind
that they are determined not only by the type of detergent used,
the conditions of the experiments and resolution of techniques
applied, but also by the type of tissue and cells used for their iso-
lation and visualization. This has to be taken into account when
comparing the data and making conclusions about the physiolog-
ical relevance of proteins detected in lipid rafts. From this point of
view a systematic meta-analysis of existing data considering var-
ious experimental conditions, tissue speciﬁcity, and resolution of
the techniques appliedmight provide a useful tool for understand-
ing raft heterogeneity and for optimizing further research into this
intriguing subject.
The best-characterized raft proteins include lipid-modiﬁed
proteins containing saturated acyl chains, such as GPI-anchored
proteins, and doubly acylated proteins, such as Src family kinases
and the α subunits of heterotrimeric G proteins (Hooper, 1999;
Liang et al., 2001; Oh et al., 2001). Many other physiologically
important proteins have been investigated for their possible raft
localizations, including key proteins involved in Alzheimer’s dis-
ease (AD), such as amyloid precursor protein (APP; Parkin et al.,
1999), β-site APP cleaving enzyme (BACE-1; Ehehalt et al., 2003;
Kalvodova et al., 2005), the γ-secretase complex (Hur et al.,
2008), a disentegrin and metalloprotease ADAM10 (Harris et al.,
2009), acetylcholinesterase (AChE; Xie et al., 2010b), angiotensin-
converting enzyme (ACE; Parkin et al., 2003), a ligand for the
Notch receptor (Jagged1; Parr-Sturgess et al., 2010), and most
recently an amyloid β (Aβ)-degrading enzyme, neprilysin (NEP;
Sato et al., 2012). However the full list of raft-associated proteins
is still far from completion.
The progress in understanding structural and functional diver-
sity of lipid rafts led to the concept of caveolae as a sub-type of
lipid rafts, appearing as 50–80 nm pits in the plasma membrane.
Although caveolae are sometimes considered to be synonymous
with lipid rafts, it is now clear that they represent only a sub-
set of rafts whose properties are deﬁned by their major protein
components belonging to the caveolin family and denoted Cav-1,
Cav-2, and Cav-3 (Parton and Simons, 1995, 2007). The charac-
terization of PTRF (polymerase I and transcript release factor,
originally identiﬁed as an RNA Pol I transcription factor, also
called Cav-P60 and now termed cavin-1) and subsequently of
other cavin family members as important constituents in caveolae
formation has revealed new levels of complexity in the biogene-
sis of these plasma membrane invaginations (Briand et al., 2011).
Like the rafts themselves, the caveolae are enriched in cholesterol,
glycosphingolipids, and SM. They are the site of several impor-
tant protein–protein interactions, for example, the neurotrophin
receptors, TrkA and p75(NTR),whose respective interactions with
caveolin regulates neurotrophin signaling in the brain (Bilderback
et al., 1999). Caveolins also regulate G-proteins,MAPK, PI3K, and
Src tyrosine kinases (Marin, 2011).
Another group of proteins which was suggested as markers of
caveolae are ﬂotillins (also known as reggies) which were discov-
ered as proteins involved in nerve regeneration (Schulte et al.,
1997). The ﬂotillins are palmitoylated and myristoylated proteins,
anchored to the plasma membrane and are considered to be exclu-
sively raft localized (Schneider et al., 2008). Flotillins belong to a
larger class of integral membrane proteins that have an evolution-
arily conserved domain called the prohibitin homology domain
(PHB) which determines the afﬁnity of proteins carrying it to the
lipid rafts (Morrow and Parton, 2005).
In the context of this review it is important to mention another
cholesterol and ganglioside enriched membrane domain, which
share some similarity but are physically and functionally dis-
tinct from the lipid rafts, the tetraspanin-enriched microdomains
(TEMs). Tetraspanins are a large family of small membrane-
spanning proteins (Yanez-Mo et al., 2011), numbering at least
32 family members in mammals. They are involved in a whole
range of cellular processes, from cell morphology and motility to
signaling pathways (Hemler, 2005).
In general, lipid rafts can be considered as signaling platforms
that bring together various ingredients of the biological mem-
branes determining speciﬁcity of the cells and their functioning.
They include receptors, channels, recognition molecules, coupling
factors and enzymes, facilitating their interaction and support-
ing signaling. Lipid rafts have been implicated in a plethora of
both physiological and pathological processes. Among beneﬁcial
processes are axonal growth and branching (Kamiguchi, 2006;
Grider et al., 2009; Munderloh et al., 2009) and hence raft disrup-
tion impedes axonogenesis (Petro and Schengrund, 2009). Rafts
are also involved in the stabilization of synapses (Willmann et al.,
2006). Raft components are also involved in cholera toxin entry via
GM1 ganglioside (Holmgren et al., 1973), HIV-1 entry (gp120),
and conversion of prion protein (PrPc) to its infectious form
(PrPSc; Fantini et al., 2002; Vieira et al., 2010). Lipid rafts play
a critical role in entry, replication, assembly, and budding of vari-
ous types of viruses (Suzuki and Suzuki, 2006). In a more general
sense, lipid rafts have been suggested to be involved in cardiovas-
cular disease, carcinogenesis, and immune systemdiseases (Michel
and Bakovic, 2007). However, this review will focus on the role of
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lipid rafts in the pathogenesis of AD, a condition with which lipid
rafts have been demonstrated to have multifarious links (Cordy
et al., 2006; Cheng et al., 2007; Vetrivel and Thinakaran, 2010).
AMYLOID CASCADE HYPOTHESIS OF AD
In the last two decades the amyloid cascade hypothesis of AD
(Hardy and Higgins, 1992) has prevailed leading to accumula-
tion of a signiﬁcant amount of data on the molecular basis of
the disease which have recently been reviewed by those who orig-
inally proposed the concept (Selkoe, 2001; Hardy, 2009). From
the clinical point of view, the disease is characterized by global
cognitive decline, associated with brain pathology involving accu-
mulation of extracellular amyloid aggregates (also known as senile
plaques) of amyloid β peptide (Aβ) and intracellular neuroﬁbril-
lary tangles of hyper-phosphorylated tau protein (Bothwell and
Giniger, 2000). According to the amyloid cascade hypothesis, it
is the Aβ which is principally responsible for many of the patho-
logical features of the disease (Hardy and Higgins, 1992; Sakono
and Zako, 2010) with Aβ oligomers representing the most toxic
species (Haass and Selkoe, 2007; Walsh and Selkoe, 2007; Sakono
and Zako, 2010). Accumulation of amyloid plaques is accom-
panied by astrogliosis and microgliosis (Grilli et al., 2003) and
the most affected brain areas are the neocortex and hippocam-
pus (Sisodia and Gallagher, 1998). Although there are strong
genetic links, including APP and presenilin mutations (Both-
well and Giniger, 2000), as well as the apolipoprotein ε4 allele
(Saunders et al., 1993; Deane et al., 2008; Huang, 2010), spo-
radic AD is the dominant form. From this point of view pre-
dominance of AD research based on the mechanisms of early
onset disease versus the broader spectrum of the factors lead-
ing to the sporadic form might be one of the reasons for the
failure of the majority of therapeutic trials and lack of any pre-
ventive measures 20 years since the amyloid hypothesis has been
proposed.
THE AMYLOID PRECURSOR PROTEIN (APP)
APP is a type I integral membrane protein. It exists in three
isoforms (APP695, APP751, and APP770), generated from differ-
ential splicing of exons 7 and 8 (Sandbrink et al., 1996). Exon
7 is homologous to protease inhibitors of the Kunitz type (KPI
domain), while exon 8 is related to the MRC OX-2 antigen in thy-
mocytes (Kitaguchi et al., 1988; Sandbrink et al., 1996). APP695
lacks both KPI and OX-2 domains, while APP751 only lacks the
OX-2 domain (Henriques et al., 2007). In terms of distribution,
APP mRNA is expressed in almost every tissue, where only the
isoform ratio differs (Araki et al., 1991). It is APP695 that pre-
dominates in neurons (Gralle and Ferreira, 2007). There are two
proteolytic pathways of APP processing (Figure 1). Amyloido-
genic processing involves sequential cleavage of APP by β- and
γ-secretases (for review see Zhang et al., 2012). This process
ultimately releases Aβ peptide, responsible in large part for the
pathogenesis of AD and a soluble ectodomain, sAPPβ. The sec-
ond, non-amyloidogenic, pathway involves α-secretase cleavage
of APP. This cleavage occurs between Lys16 and Leu17, within
the Aβ region (Allinson et al., 2003) and precludes formation of
Aβ. There is also the release of the large, soluble ectodomain,
the neuroprotective sAPPα, which is shed from the cell surface
(Allinson et al., 2004) and has been found in the CSF (Palmert
et al., 1989).
At the time when the terms were introduced, α-, β-, and γ-
secretases were activities known to cleave APP proteolytically, but
not deﬁned as speciﬁc enzymes performing the cleavage. It was
later found that BACE-1 was responsible for β-secretase activity
(Vassar et al., 1999) and that a complex of presenilin, nicastrin,
Aph-1, and Pen-2 had γ-secretase activity (Yu et al., 2000; Hooper,
2005). The α-secretase cleavage was found to be mediated by zinc
metalloproteases of the disintegrin and metalloprotease (ADAM)
family, speciﬁcally ADAM10 and ADAM17 (also known as TNFα
converting enzyme, TACE). ADAM10 was found to be the dom-
inant enzyme of APP processing in SH-SY5Y cells, given a lesser
effect of ADAM17 knockdown (Allinson et al., 2004). Recent
investigations have suggested that ADAM10 is the principal APP
secretase in primary neurons, with ADAM17 playing more of an
auxiliary role (Kuhn et al., 2010; Lichtenthaler, 2010). Allinson
et al. (2004) suggested a model whereby the group of metallo-
proteases would each contribute to greater or lesser extents to
APP cleavage in different cells and under different conditions. The
ADAMs have a wide number of substrates, including angiotensin-
converting enzyme (ACE; Allinson et al., 2004), ACE2 (Lambert
et al., 2005), the prion protein (Vincent et al., 2001) as well as each
other (Parkin and Harris, 2009). The ADAMs have been reviewed
in greater detail elsewhere (Allinson et al., 2003; Edwards et al.,
2008; van Goor et al., 2009).
RAFT LOCALIZATION OF APP
The idea that lipid rafts may somehow modulate APP cleavage
and hence affect the progression of AD has been around for over
10 years and previously reviewed (Cordy et al., 2006; Cheng et al.,
2007; Vetrivel and Thinakaran, 2010). APP itself is not generally
a raft protein, although a small proportion of APP is localized
in lipid rafts (Parkin et al., 1999). Regulation of APP raft local-
ization has been suggested to involve an interaction between the
C-terminus of APP and ﬂotillin-1 (Chen et al., 2006). A more
recent study suggested that ﬂotillin-2 may also act as a scaffolding
protein, clusteringAPP in lipid rafts. Schneider et al. (2008) postu-
lated that a transient interaction between APP and ﬂotillin-2 may
regulate endocytosis of APP, which is important for its processing.
It has also been suggested that another raft component, cholesterol,
has a role in bindingAPPpromoting its raft localization (Beel et al.,
2010) although it was earlier proposed that one of the physiologi-
cal functions of APP andAβ is to control cholesterol transport (Yao
and Papadopoulos, 2002). There is also evidence that the adaptor
protein Disabled1 (Dab1) interacts with APP regulating its pro-
cessing and that the glycoprotein reelin promotes interaction of
APP and Dab1 and their localization to lipid rafts involving phos-
phorylation by Fyn kinase (Hoe et al., 2009; Minami et al., 2011).
APP trafﬁcking to the lipid rafts was shown to be dependent on
the low-density lipoprotein receptor-related protein (LRP) which
also promotes BACE1-APP interaction (Yoon et al., 2007). On the
other hand it was also demonstrated that ApoER2, a member of
the low density lipoprotein receptor (LDL-R), negatively affects
APP internalization and its expression stimulates Aβ production
by shifting the proportion of APP from the non-raft region to the
raft membrane domains (Fuentealba et al., 2007).
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FIGURE 1 | Schematic representation of APP processing and role of its
products in AD pathology.The proteolytic processing of the large,
transmembrane, amyloid precursor protein (APP) occurs in two distinct
amyloidogenic and non-amyloidogenic pathways. The amyloidogenic
pathway involves the sequential cleavage of APP by an aspartic proteinase,
β-secretase, which releases a soluble ectodomain (sAPPβ) and the
C-terminal fragment CTF99. This, in turn, is cleaved by another aspartic
proteinase, γ-secretase, generating the transcriptional regulator APP
intracellular domain (AICD), and releasing the 39–42 amino acid amyloid-β
peptide (Aβ). Due to its very high ability to aggregation, Aβ forms dimers,
trimers, and higher level oligomers which are toxic to cells and cause
neuronal death. Formation of amyloid plaques from Aβ aggregates in
complex with other proteins is a hallmark of AD but is considered as a
scavenging process. In the non-amyloidogenic pathway APP molecules are
cleaved at the α-secretase site within the Aβ-domain releasing a soluble
ectodomain sAPPα and the C-terminal fragment CTF83. Proteolytic
cleavage of CTF83 by γ-secretase releases AICD and p3 fragment whose
functions are still unknown. The AICD fragment produced in the
amyloidogenic pathway binds to a stabilizing factor Fe65 and in a complex
with other factors (the histone acetyl transferase, Tip60, and a Mediator
complex subunit Med12) can act as transcription factor regulating
expression of a variety of genes, including an Aβ-degrading enzyme
neprilysin. This process was found to be speciﬁc to the neuronal APP695
isoform. AICD produced in the non-amyloidogenic pathway and from other
APP isoforms (APP751 and APP770) is most likely to be degraded (e.g., by
some intracellular proteases, e.g., insulin-degrading enzyme). Soluble APP
ectodomains, sAPPα, and sAPPβ, have been shown to have
neuroprotective properties.
DEPENDENCE OF APP SECRETASES ON RAFT LOCALIZATION
In search of an explanation as to how APP could be cleaved in
two distinct (amyloidogenic and non-amyloidogenic) pathways, it
was suggested that APP was present in two cellular pools (Ehehalt
et al., 2003) as schematically presented in Figure 2. Amyloido-
genic processing was suggested to be linked to lipid rafts as their
integrity was critical for Aβ formation (Simons et al., 1998; Cordy
et al., 2003; Ehehalt et al., 2003; Rushworth and Hooper, 2011)
and Aβ production was also indicated to be raft-localized (Lee
et al., 1998). Furthermore, the precise protein/lipid composition
of the rafts was shown to inﬂuence Aβ release (Lemkul and Bevan,
2011) and aggregation (Ikeda et al., 2011). Tetraspanins were also
shown to regulate APP processing (Yanez-Mo et al., 2011) and per-
turbation of tetraspanin enriched domains (TEMs) can affect cell
signaling pathways (Hemler, 2005). For example, the α-secretase
ADAM10 is regulated by tetraspanins and in this way, tetraspanins
can affect thenon-amyloidogenic processingofAPP (Arduise et al.,
2008). In addition to this, tetraspanins also regulate the amyloido-
genic pathway of APP processing since γ-secretase was shown to
be associated with TEMs (Wakabayashi et al., 2009).
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FIGURE 2 |Topography of APP processing in cell membrane and lipid
rafts.The lipid raft is shown as part of the plasma membrane. The
phospholipid domain (light blue) is separate from the lipid raft. The latter is
enriched in glycosphingolipids and sphingomyelin (red) on the exofacial
leaﬂet and glycerolipids (e.g., phosphatidylserine and
phosphatidylethanolamine; green) on the cytofacial leaﬂet. Cholesterol
(black) is enriched in both leaﬂets. The acyl chains in lipid rafts are more
able to pack together. APP (Aβ region in maroon) is localized in raft and
non-raft fractions, but predominates outside rafts. The α-secretase is not
raft-associated, while the β- and γ-secretases predominate in rafts. The cell
surface is shown for clarity, although β-cleavage predominantly occurs in
endosomes.
BACE-1 was found to be palmitoylated at three residues, which
indicated possible raft localization and interaction with raft-
resident lipids (Kalvodova et al., 2005; Hattori et al., 2006). When
BACE-1 was targeted to lipid rafts via GPI-anchoring, production
of Aβ was increased, indicating upregulation of amyloidogenic
APP processing (Cordy et al., 2003). A more recent study suggests
that GPI-anchorage increases preferential cleavage at the β-site of
APP, producing the full length Aβ, whereas wtBACE-1 cleaves APP
at two sites (β and β’ sites) producing full length and N-terminally
truncatedAβ (Vetrivel et al., 2011). Another study has reported the
effects of GPI-anchorage of ADAM10, the principal α-secretase,
and showed that no wtADAM10 was raft localized while all GPI-
ADAM10 was in lipid rafts. It was associated with a reduction in
Aβ as GPI-ADAM10 competed with BACE-1 for theAPP substrate
(Harris et al., 2009).
In addition to BACE1, it was shown that the subunits of
the γ-secretase complex are also enriched in the lipid rafts (Lee
et al., 1998; Hur et al., 2008) and that S-palmitoylation plays a
role in localization and stability of nicastrin and Aph-1 within
the rafts although not affecting the γ-secretase processing of
APP (Cheng et al., 2009). While caveolin-1 was shown to be
an important regulator of γ-secretase spatial distribution and
activity (Kapoor et al., 2010), the proteins of the γ-secretase
complex, e.g., PS1, in turn, can induce lipid raft formation and
decrease the membrane ﬂuidity (Eckert and Müller, 2009). A sub-
set of proteins, in particular voltage-dependent anion channel
1 and contact in associated protein 1, are also associated with
γ-secretase in lipid rafts and affect APP processing (Hur et al.,
2012).
Another important lipid-raft associated protein which was
shown to play an important role in APP processing is the GPI-
anchoredprionprotein (PrP;Naslavsky et al., 1997). Itwas demon-
strated that PrPc regulates APP processing by inhibiting BACE1
activity and that the effect of PrPc on the β-secretase cleavage of
APP requires the localization of PrPc to cholesterol-rich lipid rafts
and is mediated by the N-terminal polybasic region of PrPC via
interaction with glycosaminoglycans (Parkin et al., 2007). This
interaction decreased BACE1 at the cell surface and in endosomes
where it preferentially cleaves wild type APP but increased it in
the Golgi where it preferentially cleaves APP with the Swedish
mutation (APPSwe). Although deletion of PrPc in transgenic mice
expressing human mutated APPSwe,Ind had no effect on APP pro-
cessing and Aβ levels, deletion of PrPc in HEK293 cells expression
wild type reduced APP cleavage by BACE1. Because there was no
effect of PrPc deletion on processing of APPSwe in HEK cells the
authors suggested that PrPc may be a key protective player against
sporadic Alzheimer disease versus its less common familiar form
(Grifﬁths et al., 2011). Because there is no detected decrease of
PrPc content in the AD brain (Saijo et al., 2011) it is possible to
suggest that age- and disease-dependent disruption of lipid rafts
might be a cause of decreased ability of PrPc to control BACE1
activity resulting in accumulation of Aβ peptide in the case of
sporadic AD.
The amyloid-degrading enzyme, NEP, has been shown to be
partially associated with lipid rafts in human synoviocytes in
“ectopeptidase-rich membrane microdomains” (Riemann et al.,
2001), and also in pre-B and B cell lines (Nalm-6 and Raji; Ange-
lisová et al., 1999). By targeting NEP to different intracellular
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compartments of neurons, including the lipid rafts, Hama and
colleagues demonstrated that the endogenous targeting signal in
wild-type NEP is well optimized for the overall neuronal clear-
ance of Aβ (Hama et al., 2004). Only the mature, fully glycosylated
form of NEP, preferentially in its dimerized form, can be found
in lipid rafts in direct association with phosphatidylserine (Hama
et al., 2004). These authors also suggested that the localization of
NEP in different intracellular compartments may be involved in
the metabolism of distinct pools of Aβ and that the endogenous
targeting signal in wild-type NEP is well optimized for the overall
neuronal clearance of Aβ. The partitioning of NEP into lipid rafts
has also recently been conﬁrmed by Sato and colleagues (Sato
et al., 2012). Although another Aβ-degrading enzyme, insulysin
(insulin-degrading enzyme, IDE), is primarily a cytosolic protein
it is also, in part, associated with lipid rafts where it may facilitate
Aβ clearance (Bulloj et al., 2008).
SUB-CELLULAR LOCALIZATION OF APP PROCESSING
Apart from compartmentalization within the lipid rafts, the amy-
loidogenic processing pathway was shown to be dependent on
endocytosis (Ehehalt et al., 2003). In addition to ﬂotillin, caveolin-
1 is responsible for partitioning of γ-secretase between the
plasmamembrane and endosomes and cells depleted of caveolin-1
had more γ-secretase localized within the clathrin-coated non-
caveolar endocytic vesicles, although different caveolins have been
shown to have different effects on APP processing (Nishiyama
et al., 1999; Kapoor et al., 2010).
Lipid rafts affect APP processing not only through favoring
interactions between APP and BACE-1 but also by promot-
ing endocytosis of APP. This process was shown to be APP
isoform-dependentwith theneuronalAPP695 isoform tobemostly
processed via the β-secretase pathway whereas APP751 and APP770
mainly undergo α-secretase cleavage (Belyaev et al., 2010). Some
of the earliest work about subcellular localization of APP process-
ing indicated that sAPPβ could be detected in neuronal NT2N
cell lysates with the absence of sAPPα or p3 fragments. This sug-
gested an intracellular β-secretase pathway (Chyung et al., 1997;
Hartmann et al., 1997). It is worth noting that the β-secretase
pathway operates differently with wild-type APP (wtAPP) and
APP carrying the Swedish mutation (APPSw; Haass et al., 1995;
Grifﬁths et al., 2011). An alternative trafﬁcking pathway has been
recently reported, whereby APP can bypass endosomes and be
trafﬁcked directly to the lysosomes. This, though, does not occur
with either APPSw or APPLondon variants suggesting that these
mutations affect APP transit (Lorenzen et al., 2010).
LIPID RAFTS AND THE APP INTRACELLULAR DOMAIN (AICD)
Although there is quite a substantial amount of data on the phys-
iological role of N-terminal soluble ectodomains of APP – sAPPα
and sAPPβ, for review see Chasseigneaux and Allinquant (2012),
the C-terminal products of APP proteolytic cleavage have only
recently started to attract special attention. It is now rather well
documented (although not without some controversy) that the
C-terminal fragment of APP, AICD, can act as a transcription fac-
tor (Cao and Sudhof, 2001; Leissring et al., 2002; Schettini et al.,
2010). The controversy of the AICD research has been under-
pinned by utilization of different cell types expressing different
APP isoforms and by the difﬁculties in detecting AICD due to its
very short half life (Cupers et al., 2001). However, it was repeatedly
demonstrated that functional AICD, which translocates to the cell
nucleus and up-regulates expression of a reporter NEP gene, is
produced only via the amyloidogenic pathway and only from the
APP695 isoform (Goodger et al., 2009; Belyaev et al., 2010). This
process was also shown to be neuronal cell speciﬁc and lipid raft
dependent (Belyaev et al., 2010). In an earlier work by Cao and
Sudhof (2001), a yeast 2-hybrid (Y2H) screen was used to identify
binding partners of the C-terminal domain of APP which revealed
the role of Fe65 and the histone acetyltransferase (HAT) Tip60 in
formation of functionally active AICD.
AICD regulates the transcription of several target genes, some
better characterized than others (Beckett et al., 2012; Pardossi-
Piquard and Checler, 2012). The most well documented gene up-
regulated by AICD is of the amyloid-degrading enzyme neprilysin
(Pardossi-Piquard et al., 2005; Belyaev et al., 2009). However, there
is also evidence that APP itself (von Rotz et al., 2004), BACE1 (von
Rotz et al., 2004), GSK-3β (Kim et al., 2003) and aquaporin-1
(Huysseune et al., 2009) can be regulated by AICD. In addition to
APP, regulation of the GSK-3β can be considered as a link between
AICD andADpathology especially taking into account the data on
elevated levels of AICD in the brain of AD patients (Ghosal et al.,
2009). Moreover, the ability of AICD to regulate expression of APP
and BACE1 suggests a feedback mechanism of its own regulation
by proteolytic processing of its precursor (Grimm et al., 2012a).
AICD also has a direct link to lipid metabolism as it has been
found to suppress the expression of the major lipoprotein recep-
tor LRP1 and as such affect apoE/cholesterol metabolism (Liu
et al., 2007). On the other hand AICD controls expression of the
alkyldihydroxyacetonephosphate-synthase which regulates plas-
malogen synthesis in the cells (Grimm et al., 2011b) and reduced
levels of these brain-speciﬁc lipids are characteristic of the AD
brain (Han et al., 2001; Rothhaar et al., 2012). Reduced plasmalo-
gen levels in the AD brain might have direct effect on production
of Aβ since they were shown to inhibit activity of γ-secretase
(Rothhaar et al., 2012). There is also evidence that AICD regulates
sphingolipid synthesis via serine-palmitoyl transferase (Grimm
et al., 2011a), and as such may control composition of lipid rafts
andAPP processing. The wide range of putativeAICD target genes
highlights the role of APP signaling in normal brain functioning
and in AD pathology.
LIPID RAFT COMPONENTS AND THEIR CHANGES IN AD
SPHINGOMYELIN
The major component of lipid rafts, sphingomyelin (SM), is
characteristic only for eukaryotic cells where it comprises about
10–15% of total phospholipids and even more in the brain and
peripheral nervous tissue. SM and its metabolites play an impor-
tant role as secondmessengers in signal transduction events during
development, differentiation and immune response of the organ-
isms (Nalivaeva et al., 2000;Hannunet al., 2001). SM is essential for
the activity of some types of receptors, including the α7 nicotinic
receptor (Colón-Sáez andYakel, 2011),NMDA receptors (Wheeler
et al., 2009), neurotrophic tyrosine kinase receptor type 2 (Trovò
et al., 2011), serotonin1A receptor (Jafurulla et al., 2008) and the
urokinase receptor (uPAR; Sahores et al., 2008). It was also found
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that some disease-related membrane proteins (APP, gp120, and
PrP) have a common SM-recognition site which underscores the
role of lipid rafts in AD, HIV, and prion diseases (Mahfoud et al.,
2002).
Investigation of lipid raft biology was enhanced by the discov-
ery of SM-speciﬁc probes, e.g., lysenin, which serve as powerful
tools to study the organization and biological function of this lipid
in biological membranes (Hullin-Matsuda and Kobayashi, 2007;
Shogomori and Kobayashi, 2008). These studies have demon-
strated functional and structural diversity of lipid rafts and char-
acterized in the plasma membrane of Jurkat T cells the SM-rich
domains which had spatial and functional speciﬁcity compared
to the GM1-rich domains (Kiyokawa et al., 2005). Formation of
SM clusters in the membranes of neuronal cells was shown to
depend on localization of SM synthase (SMS) isoforms in various
cell compartments and that the activity of SMS is the rate-limiting
step in SM cluster formation. In accordance with this it was also
demonstrated that SM clusters were formed only in the vicinity
of SM synthase proteins. In particular, it was also found that the
SMS2 isoform is speciﬁc for the dendrites of hippocampal neu-
rons (Kidani et al., 2012). The pattern of individual species of
sphingomeylin was also found to be different in various types
of cells and even in cell compartments (e.g., in lipid rafts ver-
sus detergent-soluble fractions) which testiﬁes to the role of these
lipids in determining cell-speciﬁc membrane properties (Valsecchi
et al., 2007).
In the aging brain and especially in AD pathology, lipid metab-
olism, and in particular that of SM, undergoes signiﬁcant changes.
By using a shotgun lipidomics approach Han and colleagues have
compared levels of over 800 lipid species in control and AD brains
and demonstrated a signiﬁcant decrease in SM and increases in
ceramide levels in the affected brain. They suggested a model in
which an AD-related increase in SMase activity results in faster
SM hydrolysis (and increased ceramide production) which would
lead to alterations in lipid raft formation (Han et al., 2011). These
authors also hypothesized that this would impair functions of
GLUT4, which was previously shown to be functionally linked
to lipid rafts (Michel and Bakovic, 2007) and lead to the dysfunc-
tions in energy homeostasis characteristic of the disease.Moreover
it was also shown that accumulation of the amyloid peptide in
neuronal cells leads to SMase activation and SM depletion which,
in turn, affects cellular trafﬁcking and abnormal APP process-
ing (Soreghan et al., 2003). Further work demonstrated that the
most toxic form of amyloid peptide Aβ42 can also activate SMase
(Grimm et al., 2005; Grosgen et al., 2010). Since excessive SMase-
mediated cleavage of SM occurs early in AD it is likely to disrupt
a range of protein-lipid interactions and hence downstream sig-
naling pathways (Haughey et al., 2010). In addition to AD-linked
SMase over-activity, there have been reports of deﬁciencies of the
enzymes responsible for sphingolipid synthesis (Piccinini et al.,
2010).
GANGLIOSIDES
Gangliosides are glycosphingolipids with one or more sialic
acid residues. They are essential components of all animal cell
membranes where they are anchored in the external leaﬂet by
the hydrophobic ceramide part of their molecule while the
oligosaccharide chain protrudes into the extracellular medium.
Gangliosides are particularly abundant in the plasma membranes
of neuronal cells (Sonnino et al., 2007) have been implicated in
various cellular functions since the high heterogeneity of their
oligosaccharide structures allows speciﬁc interactions with var-
ious proteins and oligosaccharide chains of other molecules at
the cell membrane surface. Gangliosides to a great extent deter-
mine the ﬁne structure of membranes, e.g., lateral diffusion of
its components, as well as the organization of lipid rafts (Cantù
et al., 2011). Disruption of ganglioside metabolism leads to vari-
ous neurological diseases (for review seeWalkley, 2003). Studies of
ganglioside-knockout mice have demonstrated that depletion of
various classes of gangliosides results in development of neurode-
generation and pathology similar to Alzheimer’s or Parkinson’s
diseases (Furukawa et al., 2011; Wu et al., 2011). In the aging
brain, and especially in AD patients, ganglioside content signiﬁ-
cantly decreases in various brain structures, especially in the areas
of the brain related to the pathogenesis of the disease (Kracun
et al., 1991).
The link of gangliosides with AD pathology has been mostly
related to their localization in lipid rafts which have been sug-
gested to act as a platform for GM1-induced aggregation of Aβ
peptide (Parton, 1994; Zha et al., 2004; Ariga et al., 2008). Labeled
Aβ shows high afﬁnity for GM1 containing membranes, suggest-
ing that GM1 acts as an Aβ binding molecule (Kakio et al., 2004).
It has been suggested that the N-terminal region of Aβ interacts
with GM1 clusters through hydrogen bonding and electrostatic
interactions (Lemkul and Bevan, 2011). It was also suggested that
cholesterol may facilitate GM1 clustering (Kakio et al., 2001).
Extraction of cortical lipid rafts from human AD brains showed
an increase in both GM1 and GM2 (Molander-Melin et al., 2005)
despite an overall reduction of gangliosides (Ariga et al., 2008).
There are data indicating that gangliosides accumulate in senile
plaques and that they may be involved in the conversion of Aβ to a
neurotoxic oligomeric form (Molander-Melin et al., 2005; Okada
et al., 2008).
Various synaptosomal and liposomal studies have suggested
that GM1 accelerates formation of amyloid ﬁbrils (Yamamoto
et al., 2004; Zha et al., 2004). Further analysis of the role of
lipid rafts in Aβ aggregation have conﬁrmed that raft proteins
do not play a signiﬁcant role in this process as proteinase K or
SDS treatment did not affect the aggregation-promoting capacity
of the rafts. Moreover, the cholesterol-depleting agent methyl-β-
cyclodextrin (MβCD) also did not have an effect on Aβ oligomer-
ization (Kim et al., 2006). Further cell studies reinforce the role of
gangliosides in Aβ aggregation. Rafts taken from ganglioside rich
cells (C2C12) were able to induce Aβ aggregation more potently
than ganglioside-poor cells (HeLa and SK-N-MC). Similarly, rafts
isolated from brain tissue rich in gangliosides were able to increase
Aβ aggregation compared to rafts isolated from the liver with
lower ganglioside content. Also, CHO-K1 cells genetically deﬁ-
cient in the synthesis of complex gangliosides had lower levels of
Aβ aggregation than the wild type cells (Kim et al., 2006).
An examination of the effects of GM1 on APP processing in
SH-SY5Y and COS7 cells showed an inhibition of α-cleavage (Zha
et al., 2004). On the other hand, Aβ1–40 oligomers were found
to stimulate the amyloidogenic processing of APP by reducing
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membrane ﬂuidity and complexing with GM1 ganglioside (Peters
et al., 2009). Although precise mechanisms of GM1 changes with
age are still unknown it was demonstrated that GM1 content
in neuronal membranes, particularly in DRM microdomains,
increases with age and this increase was more pronounced in
the brain of apoE4 knock-in mice compared to apoE3 knock-in
animals (Yamamoto et al., 2004).
Recently two novel mechanisms linking gangliosides with AD
have been described byGrimmet al. (2012b). They discovered that
Aβ binds to GD3-synthase (GD3S, the key-enzyme in converting
a-series gangliosides to major brain speciﬁc b-series) and inhibits
its activity.On the other hand, theAPP intracellular domainAICD,
together with Fe65, was found to down-regulate expression of the
GD3S gene. This provides an explanation for age-dependent and
AD-related changes in brain ganglioside patterns and supports
an essential role of APP in ganglioside homeostasis. Another link
between gangliosides and AD lies in their ability to alter APP pro-
cessing. As observed by the authors, GM3 was able to decrease
production of Aβ while GD3 was shown to increase its levels in
COS7 cells. This might be related to the changes in the proper-
ties of lipid rafts containing different amounts of GM3 or GD3
ganglioside species and their ability to regulate activity of β- and
γ-secretases.
Taking into account the important role of gangliosides in nor-
mal brain function, their involvement in the pathogenesis of AD
should be treated with caution since different species of ganglio-
sides will have a different impact on the integrity and properties
of neuronal membranes. Recently, by using G3 synthase KO mice
(lacking only b-series gangliosides) and GM2/GD2 synthase KO
mice (which lack almost all gangliosides except GM3 and GD3)
it was found that these ganglioside species are important for neu-
roprotection and anti-inﬂammatory response via maintenance
of lipid rafts (Ohmi et al., 2011). Intraventricular treatment of
AD patients with GM1 was shown to stop the progression of
cognitive deterioration and improve motor performance and neu-
ropsychological assessments (Svennerholmet al., 2002). Peripheral
utilization of GM1 for prevention of Aβ aggregation in the brain
via establishing peripheral/brain dynamics of Aβ was suggested as
a possible therapeutic approach for AD since in the PS/APP mice
this was shown to reduce Aβ accumulation in the brain (Matsuoka
et al., 2003). However, due to the antigenic properties of ganglio-
sides this might provoke some side-effects (López-Requena et al.,
2007).
CHOLESTEROL
Another important component of cellularmembranes and of lipid
rafts, cholesterol, has been recently extensively reviewed in relation
to its role in AD (Marzolo and Bu, 2009; Burns and Rebeck, 2010;
Mathew et al., 2011). The picture is by no means a simple one with
cholesterol being ascribed both positive and negative roles. Indeed,
other diseases are also linked to cholesterol, while it remains
unclear which are speciﬁcally raft-associated. Such pathologies
include Smith–Lemli–Opitz syndrome, Huntington’s disease and
Niemann–Pick Type C disease (Korade and Kenworthy, 2008). In
terms of normal aging, the data seem to show that the changes in
cholesterol are highly dependent on the brain region and cell types
used in the studies (Martin et al., 2010).
Cholesterol levels have been shown tobe elevated inADpatients
as well as the levels of cholesterol precursors in the mevalonate
pathway, farnesylpyrophosphate, and geranylgeranylpyrophos-
phate (Hooff et al., 2010; Kolsch et al., 2010). However, this
view is by no means unanimous and other groups have found
lower levels of cholesterol in AD brains (Kolsch et al., 2010;
Leduc et al., 2010), in addition to its precursors lanosterol and
lathosterol (Kolsch et al., 2010), with lower levels of its synthesiz-
ing enzyme, HMG CoA reductase (Leduc et al., 2010). However,
quantiﬁcation of global cholesterol levels are not necessarily reﬂec-
tive of the number or distribution of lipid rafts (Leduc et al.,
2010).
As cholesterol is integral to ordered lipid rafts, the consequences
of cholesterol depletion are widely regarded as effects of raft dis-
ruption (Hao et al., 2001; Mondal et al., 2009). In this context
the cholesterol content in the membranes has an inversely propor-
tional relationship with the membrane-perturbing effects of Aβ
oligomers (Cecchi et al., 2009). As such, if cholesterol increases do
elevate lipid raft abundance, then it would increase Aβ formation
(Simons et al., 1998; Ehehalt et al., 2003) and, on the contrary, low
cholesterol levels will lead to up-regulation of the activity of the
α-secretase, ADAM10 (Kojro et al., 2001). Cholesterol depletion
in cells by MβCD was shown to affect APP-processing and for-
mation of functionally active AICD resulting in reduced levels of
expression of the amyloid-degrading enzyme, neprilysin (Belyaev
et al., 2010). On the other hand, cholesterol has been shown to
bind C99, which promotes amyloidogenic processing (Beel et al.,
2010) and the increase of Aβ levels, in turn, can cause changes
in cholesterol homeostasis in the Golgi and plasma membrane
(Igbavboa et al., 2009). Formation of the Aβ “seed” and initiation
of Aβ aggregation was also shown to be cholesterol dependent
(Mizuno et al., 1999; Kakio et al., 2001; Simons et al., 2001). In
a more biophysical sense, raised cholesterol has been implicated
in facilitating the insertion of Aβ into the plasma membrane. In
so doing, Aβ then destroys the cells’ membrane integrity (Ji et al.,
2002).
Just as cholesterol and lipid rafts have been shown to affect
APP processing, APP-derived species have been shown to impact
on cholesterol and lipid homeostasis. Aβ peptides modulate the
metabolism of cholesterol, in particular its esteriﬁcation rate, and
of phospholipids in hepatocytes, neuronal cells, and in the entire
brain (Koudinov et al., 1996; Koudinova et al., 1996, 2000). It was
also found that Aβ peptides alter vesicle trafﬁcking and choles-
terol homeostasis (Liu et al., 1998). On the other hand, it was
shown that cholesterol binds to APP at the α-secretase cleavage
sites and Aβ itself can bind cholesterol and prevent its interac-
tion with low-density lipoprotein (Yao and Papadopoulos, 2002).
This conﬁrmed that Aβ might act as a component of lipoprotein
complexes and affect reverse cholesterol transport from neuronal
tissue to the periphery in addition to its role in cholesterol synthe-
sis and intracellular dynamics (Koudinov et al., 2001; Michikawa
et al., 2001). In a later study Aβ40 has been shown to inhibit a key
enzyme in the biosynthesis of cholesterol, HMG CoA reductase
(Grimm et al., 2005). Further to this, APP intracellular domain
AICD was found to regulate cholesterol levels via LRP1 (Grosgen
et al., 2010). However, there also are data reporting that choles-
terol in physiological concentrations can protect neuronal cells
Frontiers in Physiology | Membrane Physiology and Biophysics June 2012 | Volume 3 | Article 189 | 8
Hicks et al. Lipid rafts and AD
against Aβ-induced toxicity and slow down the process of forma-
tion of toxic aggregates of Aβ with metal ions, in particular with
aluminum (Granzotto et al., 2011). This correlates with the data
suggesting that cholesterol may have a protective effect against
membrane disruption by amyloid species (in this case,Aβ-derived
diffusible ligands: ADDLs). Cholesterol supplemented SH-SY5Y
cells were shown to display reduced binding of ADDLs to the
plasma membrane, while oligomers increased in membrane pres-
ence after treatment with the cholesterol-depleting agent MβCD
(Cecchi et al., 2009).
STATINS
Statins are a class of drugs which inhibit HMG CoA reductase,
a key enzyme in the biosynthesis of cholesterol. Given the links
between cholesterol and AD, it is not surprising that there are
multiple investigations on the effects of statins in AD pathology.
The current state of the ﬁeld and problems have been recently
discussed and the role of statins has been reviewed (Wang et al.,
2010; Wood et al., 2010). The authors point out that the effects of
statins are not only related to APP processing nor speciﬁc for the
AD pathology. Furthermore, the physiological effects of statins are
not solely due to inhibition of cholesterol biosynthesis but include
perturbation of other mevalonate-dependent pathways such as
protein prenylation.
A number of studies have shown positive effects of statins in
AD (Jick et al., 2000; Buxbaum et al., 2001, 2002). This is in agree-
ment with the previous studies demonstrating that depletion of
cholesterol reduces Aβ in cultured neurons (Simons et al., 1998).
One recent studyhas suggested that ﬂuvastatin is able tomodify the
trafﬁcking of APP.Use of this drugwas stated to increase lysosomal
degradation of APP C-terminal fragments (CTFs) and hence facil-
itate Aβ clearance (Shinohara et al., 2010). However, the reduction
in Aβ levels is not necessarily linked with the cognitive beneﬁts.
A recent randomized, double-blinded, placebo-controlled trial of
simvastatin showed reduced Aβ in treated patients, but no cor-
responding improvement in cognitive performance (ADAS-Cog
score; Sano et al., 2011). The biochemical studies are fairly uniform
in that cholesterol depletion results in reductions in key AD-
related markers. However, the results of epidemiological research
are unequivocal. The CochraneDementia andCognitive Improve-
ment Group study reported that statin treatment had no effect
on the prevention or treatment of dementia (McGuinness et al.,
2009a,b). However, taking into account the highly variable rela-
tionship between the initiation of statin therapy and the time and
severity of the AD, it is very difﬁcult to get a conclusive assess-
ment of the accumulated data on the beneﬁcial effect of statins
and any such study should use a deﬁned set of criteria during
epidemiological meta-analysis (Shepardson et al., 2011a,b).
LIPID RAFTS AND CELL SIGNALING
Lipid rafts have been implicated as the sites for a great number of
signaling pathways (Allen et al., 2007). Perturbation of, or changes,
in lipid rafts could therefore affect neuronal signaling, includ-
ing cholinergic transmission. As cholinergic hypofunction is key
to the pathogenesis of AD (Schliebs, 2005; Schliebs and Arendt,
2006), there are strong links between lipid rafts, neuronal signaling
pathways, and AD.
LIPID MEDIATORS
Various lipids, such as eicosanoids, docosanoids, and cannabi-
noids, can act as signaling mediators and their abnormal
metabolism has implications in AD (Farooqui, 2011). These lipid
mediators can modulate the metabolism of sphingolipids through
activation of SMases. Furthermore, sphingolipid-derived mole-
cules such as ceramide and ceramide 1-phosphate can act as lipid
mediators and accumulate in the AD brain. This accumulation
of sphingolipid derivatives can activate cytosolic phospholipase
A2 (cPLA2), which leads to changes in membrane ﬂuidity and
permeability with concomitant alterations in ion homeostasis.
Furthermore, the degradation products of cPLA2 metabolism are
often pro-inﬂammatory (Frisardi et al., 2011). This work shows
how the lipid raft constituents, in this case sphingolipids, can affect
AD processes in an APP-independent manner. Here, accumula-
tion and action of these lipid mediators promotes inﬂammation,
a process characteristic of AD (Akiyama et al., 2000).
NEUROTRANSMITTER SIGNALING
Numerous neurotransmitter signaling systems, especially recep-
tor function, are inﬂuenced by lipid rafts. The range of recep-
tors involved is all-encompassing, including ionotropic receptors
such as α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid
(AMPA receptors), γ-aminobutyric acid (GABA) receptors, N -
methyl-d-aspartate (NMDA), and nicotinic acetylcholine (nACh)
receptors. The inﬂuence of lipid rafts also extends to metabotropic
G-protein coupled receptors, such as the muscarinic acetylcholine
receptor (mAChR; Allen et al., 2007; Rushworth and Hooper,
2011). Although all these signaling systems can be linked to AD,
it is the cholinergic system which is of central importance, as its
hypofunction is considered one of the hallmarks of the disease
(Coyle et al., 1983; Auld et al., 2002; Schliebs and Arendt, 2006)
and its involvement is therefore principally considered here.
THE CHOLINERGIC SYSTEM AND THE α7 NICOTINIC ACETYLCHOLINE
RECEPTOR
Lipid rafts have been implicated in regulating the clustering of
nAChRs via the myristoylated peripheral membrane protein, rap-
syn, which is constitutively lipid raft localized. Perturbation of
the rafts impedes the interaction between rapsyn and nAChRs,
which reduces clustering of the receptors and hence their function
(Zhu et al., 2006). Protein reconstitution studies using lipid vesi-
cles imply that the partitioning of the nAChR into raft domains is
not solely due to the intrinsic biophysical properties of the recep-
tor but requires a signaling event to translocate the protein into
speciﬁcmembranedomains (Bermúdez et al., 2010). Furthermore,
cholesterol affects the properties,both structural and functional,of
some acetylcholine receptors (Barrantes et al., 2010). Agrin signal-
ing represents one pathway which can enhance the translocation
of the nAChR into lipid rafts (Campagna and Fallon, 2006; Zhu
et al., 2006).
In particular, one of the most prominent examples of a lipid
raft-linked signaling protein is the α7 nicotinic acetylcholine
receptor (nAChR), a Ca2+ channel (Albuquerque et al., 2009),
which has a close involvement with Aβ and cognitive decline
(Albuquerque et al., 2009; Jurgensen and Ferreira, 2009; Hernan-
dez et al., 2010). On balance, the α7 nAChR seems to have a
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neuroprotective role in model systems. Signiﬁcant amounts of the
α7 nAChR are associated with lipid rafts and these rafts are essen-
tial for maintenance of function (Bruses et al., 2001). Lipid rafts
appear to assist the interaction between soluble Aβ and the recep-
tor (Khan et al., 2010). Although α7 KO mice show no apparent
cognitive defects, Aβ42 is enriched and Aβ oligomers are enhanced
in hippocampi from these animals (Hernandez et al., 2010).
The α7 nAChR regulates, in part, the pleiotropic intracellular
signaling effects of Ca2+. In addition to this, the receptor is closely
linked to the signaling of cAMP (via adenylyl cyclase) as well as
the kinases Fyn and PI3K (Oshikawa et al., 2003). Disruption of
lipid rafts with MβCD or SMase has signiﬁcant effects on receptor
desensitization kinetics (Colón-Sáez and Yakel, 2011) and hence
the many important downstream signaling events. Additional
interactions of the α7 nAChR have been assessed using a pro-
teomic screen,which identiﬁed several proteins involved in neurite
outgrowth and maintenance, namely α-catenin 2, BASP1/NAP-22,
gelsolin, homer 1, and neuromodulin (Paulo et al., 2009). Further
to this, the AD therapeutic donepezil protects against glutamate
toxicity in part through stimulation of the α7 nAChR (Shen et al.,
2010). Given the central role of the α7 nAChR, it has been sug-
gested promoting its activation via novel agonists may represent a
new therapeutic approach in AD (Wang, 2010).
ACETYLCHOLINESTERASE (AChE)
Lipid raft localization has recently been linked to another protein
of the cholinergic system, namely acetylcholinesterase (AChE),
although the functional implications of this are as yet unclear
(Xie et al., 2010b; Hicks et al., 2011). AChE inhibition by com-
pounds such as rivastigmine or galantamine represents the major
therapeutic option for treating the cognitive impairment seen in
the early stages of AD yet the relationship between AChE and AD
represents something of a paradox. AChE exists in a number of
different molecular forms (G1, G2, G4) of which the tetrameric
G4 form is predominant in brain. In AD, brain G4 AChE levels
are seen to fall as the disease progresses, while G1 and G2 lev-
els rise somewhat, as compared to normal brains (Atack et al.,
1983; Garcia-Ayllon et al., 2010). AChE is found associated with
amyloid plaques, leading to the suggestion that AChE may pro-
mote Aβ aggregation (Moran et al., 1993; Inestrosa et al., 1996). In
some brain regions with AD pathology, virtually all of the AChE
is localized in these complexes (Mesulam et al., 1987). A direct
interaction between Aβ and AChE has been proposed, with bind-
ing occurring at the peripheral anionic site (PAS) of the enzyme.
Those AChE inhibitors which occupy the PAS (e.g., propidium)
show the most signiﬁcant reductions in ﬁbril formation (Bartolini
et al., 2003) since the catalytic site is not required for interac-
tion with Aβ (Inestrosa et al., 1996). Furthermore, monoclonal
antibodies directed against the PAS inhibit ﬁbril formation (Reyes
et al., 1997), which has led to the development of PAS blockers,
such as the DUO compounds, that also occupy the active site.
They show inhibitory activity on AChE as well as inhibition of
Aβ40 ﬁbril formation (Alptuzun et al., 2010) and have been sug-
gested as potential novel AD therapeutics targeting two facets of
the disease. The related enzyme butyrylcholinesterase (BuChE),
as well as a synthetic peptide derived from the BuChE C terminus
(BSP41), have also been shown to reduce amyloid ﬁbril formation
(Diamant et al., 2006). The correspondingAChE synthetic peptide,
however, did not signiﬁcantly affect Aβ ﬁbril formation.
AChE is not a transmembrane protein, rather it is anchored
to the plasma membrane by the proline rich membrane anchor
(PRiMA) which is a 20-kDa type I transmembrane protein which
can be acylated (Henderson et al., 2010; Xie et al., 2010b). PRiMA
contains a CRAC (cholesterol recognition amino acid consensus)
motif which sequesters PRiMA into lipid rafts and hence AChE
is also partly associated with rafts although the functional signiﬁ-
cance of this interaction is unclear (Xie et al., 2010a). It has been
suggested that the lipid raft localization and shedding of AChE
may have a certain role in the pathology of AD (Hicks et al., 2011).
PrP SIGNALING IN AD
PrP is another component of lipid rafts which was shown to act
as a cellular receptor and change Ca2+ signaling upon activation
by some ligands, e.g., by antibody cross-linking in T-lymphocytes
(Stuermer et al., 2005). PrPc was also shown to be a receptor for
Aβ oligomers at nanomolar concentrations and binding of Aβ
oligomers to PrPc results in the blockage of hippocampal LTP.
Incubation of hippocampal slices with PrP antibody abolishes the
effect of Aβ oligomers and rescues synaptic plasticity (Lauren et al.,
2009). Most recently it was demonstrated PrPc also interacts with
the NMDA receptor complex in a copper-dependent manner to
allosterically reduce glycine afﬁnity for the receptor and thatAβ(1–
42), copper chelators or PrPc inactivation all enhance the activity
of glycine at the receptor resulting in steady-state NMDAR cur-
rents and neurotoxicity. It was suggested that the physiological
role of PrPc might be related to limitation of excessive NMDAR
activity which might cause neuronal damage (You et al., 2012).
Together with the data on BACE1 regulation by PrPc this provides
a unifying molecular mechanism explaining the interplay between
toxic Aβ species, NMDA receptor-mediated toxicity and cop-
per homeostasis in pathogenesis of AD (Rushworth and Hooper,
2011).
THE “SIGNALOSOME”
It is possible for lipid rafts to modulate signaling in a general
way by affecting the activities of signaling molecules involved in
multiple pathways. These include, for example, the pleiotropic src
kinases (Arcaro et al., 2007) with effects on the PI3K-Akt signal-
ing pathway. Other raft-localized signaling proteins include the
epidermal growth factor receptor (EGFR), which associates with
caveolins (Couet et al., 1997) and is involved in diverse processes
including cell cycle regulation, endocytosis, and theMAPKcascade
(Oda et al., 2005). This has led to the concept of the signalosome,
containing interacting components of signaling pathways (e.g.,
EGFR) within lipid rafts along with other scaffolding proteins,
such as caveolins, and sequestering the complex from other inter-
acting proteins that may disrupt the signaling process. A prime
example is the CD40 signalosome associated with cell growth in B
cell lymphomas (Pham et al., 2002).
Similar signaling platforms operate in neuronal systems, such
as that involving estrogen receptor (ER) interactions (reviewed in
Marin, 2011). This signaling mechanism is linked to neurogenesis,
neuronal differentiation, synaptic plasticity, and neuroprotection
(including against Aβ). Recent research indicates that lipid rafts
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are the site of formation of a complex between the ER, insulin
growth factor 1 receptor (IGF-1R), Cav-1, and a voltage gated
anion channel, VDAC. The formation of this signaling complex
is neuroprotective but also lipid raft dependent (Marin, 2011).
The “signalosome” paradigm was developed further by Chad-
wick et al. (2011) who isolated lipid rafts in control and 3xTg
AD mice and compared their respective proteomes by mass spec-
trometry. Proteins so identiﬁed were then clustered into speciﬁc
signaling pathways, which allowed an appraisal of which lipid raft
signaling pathways may be altered in AD, rather than changes
in individual proteins. This systems biology approach indicated
that, in lipid rafts, wild-type mice had higher activation of pro-
survival pathways such as PTEN and Wnt/β-catenin, whereas
3xTg mice showed activation of p53 and JNK signaling pathways.
In addition, 3xTg mice had a deﬁcit in growth factor signaling,
neurodevelopmental signaling and signaling through the sonic
hedgehog pathway (Chadwick et al., 2011). Another proteomic
analysis extracted post-synaptic lipid rafts and used LC-MS/MS to
analyze their protein content. They found an enrichment of cell
adhesion molecules, channels/transporters and G-protein related
species. Their data linked lipid rafts to cell adhesion with cell-cell
contact regions and cell adhesion points being enriched in rafts.
Further to this, H+-ATPase and Na+-K+ ATPase are enriched in
lipid rafts, being responsible for maintaining ionic gradients and
modulating neuronal excitability. This study also found the post-
synaptic density to be associated with lipid rafts (Suzuki et al.,
2011). Among channels localized in lipid rafts and involved in
maintenance of neuronal cell homeostasis, in particular of astro-
cytes, are K+-buffering inwardly rectifying Kir4.1 channels and
the water channel AQP4 (Hibino and Kurachi, 2007). Residence
in the lipid rafts was also shown to be important for the activity of
a member of the chloride channel family, ClC-2, which is widely
expressed in the brain and other organs (Cornejo et al., 2009).
CONCLUDING REMARKS
Ever since the initial descriptions and characterizations of lipid
rafts, the ﬁeld has been beset by controversy (Pike, 2009) from their
very existence down to the very speciﬁc aspects of how to isolate
these structures in the laboratory. However, current consensus is
that lipid rafts do represent dynamic structural components of cel-
lular membranes integrating signaling events and regulating cell
functioning and that their dysregulation can lead to disease.
This review has largely concentrated on the links between lipid
rafts and AD pathology since processing of AD-related APP and
production of Aβ peptide are clearly affected by lipid rafts. AlsoAβ
signaling involves interactions of proteins resident to lipid rafts.
The mechanism underlying these effects has been examined in
some detail although numerous gaps in knowledge still remain.
Although the attempts to modulate lipid rafts and hence amy-
loidogenic processing have failed to translate into successful drugs,
some epidemiological studies still indicate that inhibition of cho-
lesterol synthesis through statin treatment might be beneﬁcial if
applied early (Solomon and Kivipelto, 2009; Shepardson et al.,
2011a,b). The complexity of AD pathology and etiology dictates
to consider involvement of lipid rafts in its pathogenesis in a more
generic way, not only as a simplistic link between cholesterol levels,
amyloid burden and cognition. More important for normal brain
functioning is to maintain lipid metabolism in the aging brain at
its normal rate and integrity.
In terms of future progress, lipid raft research might open new
avenues in regulation of the proteolytic and signaling processes
involved in AD pathology. The most recent discovery of the role of
lipid raft disruption in decreased production of the functionally
active transcriptional regulatorAICDwhichmight lead to an aber-
rant expression of its target genes including amyloid-degrading
enzymes neprilysin (Howell et al., 1995; Carson and Turner, 2002;
Belyaev et al., 2009; Liu et al., 2011), suggests that any therapeu-
tics aimed at manipulation of lipid raft composition should be
treated with caution. The role of the lipid components in cell
membrane functioning and their structural variability and adap-
tive potential is extremely important for normal functioning of
cells and organisms and much of the recent work in this area is
both novel and revealing. However, it is important to note that
these discoveries should be recognized as important advances
in cell science and not seen as stepping stones to a therapeutic
panacea.
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